Agenda & Faculty, April 19-20, 2024
Day 1 Moderated by: Prithviraj Bose
07:30
Registration Opens
08:50
Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education
Session I
09:00

Update on Systemic Mastocytosis
Jason Gotlib, MD - Stanford University School of Medicine, California
09:20

Workup and Management of Eosinophilia in 2024
Jason Gotlib, MD - Stanford University School of Medicine, California
09:40

Of Rux, Ropeg and Rusfertide – Treatment of PV comes of age
Andrew Kuykendall, MD - Moffit Cancer Center, Texas
10:00
Panel Discussion
10:30
Coffee Break
Session II
10:50

What’s happening in ET in 2024
Abdulraheem Yacoub, MD - University of Kansas, Kansas
11:10

Current status of interferons in MPNs
Lucia Masarova, MD - MD Anderson Cancer Center, Texas
11:30

Early/pre-fibrotic PMF – Diagnosis, Prognosis and Management
Pankit Vachhani, MD - The University of Alabama, Alabama
11:50
Panel Discussion
12:20
Independent Expert Discussion supported by GSK
13:05
Lunch Break
Session III
13:55

Making sense of all the prognostic models for MF
Nikolai Podoltsev, MD - Yale School of Medicine, Connecticut
14:15

JAK inhibitors for MF – where we stand in 2024
Ruben Mesa, MD - Levine Cancer Institute, Charlotte, North Carolina
14:35

Management of Anemia in Myelofibrosis – Old and New Drugs
Stephen T. Oh, MD - Washington University, Missouri
14:55
Panel Discussion
15:15
Room refresh and exhibit viewing
Session IV
15:35

Novel mechanisms of drug action in MF
Prithviraj Bose, MD - MD Anderson Cancer Center, Houston, Texas
15:55

Allogeneic Stem Cell Transplantation for MF
Jeanne Palmer, MD - Mayo Clinic, Arizona
16:15

Moving Beyond Spleen and Symptoms: Time for New Endpoints in MF?
Naveen Pemmaraju, MD - MD Anderson Cancer Center, Houston, Texas
16:35
Panel Discussion
16:55
Adjourn
08:00 Registration Opens
Day 2 Moderated by: Rami Komrokji, MD
Session V:
09:00

“Pre MDS” CHIP and CCUS
Mrinal Patnaik, MD - Mayo Clinic, Arizona
09:20

Updates on MDS diagnosis and classification
Sanam Loghavi, MD - MD Anderson Cancer Center, Texas
09:40

Update on clinical trials in HR-MDS
Naval Daver, MD - MD Anderson Cancer Center, Texas
10:00
Panel Discussion
10:20
Coffee Break
Session VI
Debate 1: Moderated by: Rami Komrokji, MD
Luspatercept is the new standard of care as first line therapy for LR-MDS
10:40

Yes
Yazan Madanat, MD - UT Southwestern Medical Center, Dallas, Texas
10:50

No
Maximilian Stahl, MD - Dana-Farber Cancer Institute, Boston, Massachusetts
11:00
Debate Discussion
11:10

Measuring the clinical benefit of therapies in Lower and higher risk MDS
Amer Zeidan, MD - Northwestern University Feinberg School of Medicine, Illinois
11:30

When and how to use Imetelstat for LR-MDS
Michael R. Savona, MD - Vanderbilt University Medical Center, Nashville, Tennessee
11:50
Panel Discussion
12:10
Industry supported independent expert discussion
12:55
Lunch Break & Group Photo
Session VII: Moderators: Rami Komrokji
13:45

Controversies in managing del 5q: early treatment and impact of other somatic mutations
Rami Komrokji, MD - MD Anderson Cancer Center, Texas
14:05

Treatment of Higher risk MDS patients not eligible for allogeneic stem cell transplant
Uma Borate, MD The Ohio State University, Ohio
14:25

How do I risk stratify MDS patients?
Rafael Bejar, MD - University of California, San Diego, California
14:45
Panel discussion
15:05
Independent expert discussion supported by Abbvie
15:50
Coffee Break
Session VIII
Fellows / Junior Debate 1: Moderated by: TBD
Treatment is needed prior to Allo-SCT
16:00

Yes
Luis Aguirre, MD - Dana-Farber Cancer Institute, Boston, Massachusetts
16:10

No
Somedeb Ball, MD - Vanderbilt University Medical Center, Nashville, Tennessee
16:20
Debate Discussion
16:40

How do I manage TP53 MDS?
David Sallman, MD - Moffit Cancer Center, Texas
17:00

Beyond allogeneic stem cell transplant in MDS: Immune therapies and CAR-T
Hany Elmariah, MD - Moffit Cancer Center, Florida
17:20

MDS/MPD
Guillermo Montalban Bravo, MD - MD Anderson Cancer Center, Houston, Texas